Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Issued Date
2022-04-08
Resource Type
eISSN
23793708
Scopus ID
2-s2.0-85128131875
Pubmed ID
35192543
Journal Title
JCI Insight
Volume
7
Issue
7
Rights Holder(s)
SCOPUS
Bibliographic Citation
JCI Insight Vol.7 No.7 (2022)
Suggested Citation
Ogbe A., Pace M., Bittaye M., Tipoe T., Adele S., Alagaratnam J., Aley P.K., Ansari M.A., Bara A., Broadhead S., Brown A., Brown H., Cappuccini F., Cinardo P., Dejnirattisai W., Ewer K.J., Fok H., Folegatti P.M., Fowler J., Godfrey L., Goodman A.L., Jackson B., Jenkin D., Jones M., Longet S., Makinson R.A., Marchevsky N.G., Mathew M., Mazzella A., Mujadidi Y.F., Parolini L., Petersen C., Plested E., Pollock K.M., Rajeswaran T., Ramasamy M.N., Rhead S., Robinson H., Robinson N., Sanders H., Serrano S., Tipton T., Waters A., Zacharopoulou P., Barnes E., Dunachie S., Goulder P., Klenerman P., Screaton G.R., Winston A., Hill A.V.S., Gilbert S.C., Carroll M., Pollard A.J., Fidler S., Fox J., Lambe T., Frater J. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight Vol.7 No.7 (2022). doi:10.1172/jci.insight.157031 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85959
Title
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Author(s)
Ogbe A.
Pace M.
Bittaye M.
Tipoe T.
Adele S.
Alagaratnam J.
Aley P.K.
Ansari M.A.
Bara A.
Broadhead S.
Brown A.
Brown H.
Cappuccini F.
Cinardo P.
Dejnirattisai W.
Ewer K.J.
Fok H.
Folegatti P.M.
Fowler J.
Godfrey L.
Goodman A.L.
Jackson B.
Jenkin D.
Jones M.
Longet S.
Makinson R.A.
Marchevsky N.G.
Mathew M.
Mazzella A.
Mujadidi Y.F.
Parolini L.
Petersen C.
Plested E.
Pollock K.M.
Rajeswaran T.
Ramasamy M.N.
Rhead S.
Robinson H.
Robinson N.
Sanders H.
Serrano S.
Tipton T.
Waters A.
Zacharopoulou P.
Barnes E.
Dunachie S.
Goulder P.
Klenerman P.
Screaton G.R.
Winston A.
Hill A.V.S.
Gilbert S.C.
Carroll M.
Pollard A.J.
Fidler S.
Fox J.
Lambe T.
Frater J.
Pace M.
Bittaye M.
Tipoe T.
Adele S.
Alagaratnam J.
Aley P.K.
Ansari M.A.
Bara A.
Broadhead S.
Brown A.
Brown H.
Cappuccini F.
Cinardo P.
Dejnirattisai W.
Ewer K.J.
Fok H.
Folegatti P.M.
Fowler J.
Godfrey L.
Goodman A.L.
Jackson B.
Jenkin D.
Jones M.
Longet S.
Makinson R.A.
Marchevsky N.G.
Mathew M.
Mazzella A.
Mujadidi Y.F.
Parolini L.
Petersen C.
Plested E.
Pollock K.M.
Rajeswaran T.
Ramasamy M.N.
Rhead S.
Robinson H.
Robinson N.
Sanders H.
Serrano S.
Tipton T.
Waters A.
Zacharopoulou P.
Barnes E.
Dunachie S.
Goulder P.
Klenerman P.
Screaton G.R.
Winston A.
Hill A.V.S.
Gilbert S.C.
Carroll M.
Pollard A.J.
Fidler S.
Fox J.
Lambe T.
Frater J.
Author's Affiliation
NIHR Imperial Biomedical Research Centre
NIHR Oxford Biomedical Research Centre
NIHR Guy's and St Thomas' Biomedical Research Centre
Oxford University Hospitals NHS Foundation Trust
Public Health England
St Mary's Hospital
Imperial College Faculty of Medicine
Mahidol University
Nuffield Department of Medicine
Guy's and St Thomas' NHS Foundation Trust
University of Oxford Medical Sciences Division
NIHR Oxford Biomedical Research Centre
NIHR Guy's and St Thomas' Biomedical Research Centre
Oxford University Hospitals NHS Foundation Trust
Public Health England
St Mary's Hospital
Imperial College Faculty of Medicine
Mahidol University
Nuffield Department of Medicine
Guy's and St Thomas' NHS Foundation Trust
University of Oxford Medical Sciences Division
Other Contributor(s)
Abstract
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.